Clinical Outcomes after Surgical Resection Combined with Brachytherapy for Uveal Melanomas
Currently, brachytherapy is the most commonly used therapeutic approach for uveal melanomas. Surgical resection by means of endoresection or exoresection is an alternative approach. The present report recounts our experience over 15 years in the treatment of uveal melanoma using a combined approach...
Gespeichert in:
Veröffentlicht in: | Journal of clinical medicine 2022-03, Vol.11 (6), p.1616 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 6 |
container_start_page | 1616 |
container_title | Journal of clinical medicine |
container_volume | 11 |
creator | Relimpio-López, Isabel Garrido-Hermosilla, Antonio Manuel Espejo, Francisco Gessa-Sorroche, María Coca, Lourdes Domínguez, Belen Díaz-Granda, María Jesús Ponte, Beatriz Cano, María José Rodríguez de la Rúa, Enrique Carrasco-Peña, Francisco Míguez, Carlos Saavedra, Jonathan Ontanilla, Antonio Caparrós-Escudero, Carlos Ríos, Juan José Terrón, José Antonio |
description | Currently, brachytherapy is the most commonly used therapeutic approach for uveal melanomas. Surgical resection by means of endoresection or exoresection is an alternative approach. The present report recounts our experience over 15 years in the treatment of uveal melanoma using a combined approach of resection surgery with brachytherapy. This is a single-center observational retrospective cohort study in which we describe clinical outcomes, complications and survival in 35 cases of melanoma of the iris or the ciliary body after a combination of surgery and brachytherapy or brachytherapy alone. Local treatment of the tumor was successful in all cases with surgery and brachytherapy. The most frequent complications were scleromalacia, bullous keratopathy, retinal toxicity, cataracts, hypotonia, and photophobia. There were three cases of recurrence, all of which were found in the group of patients who had received brachytherapy alone, and in one case we had to perform a secondary enucleation due to tumor growth after brachytherapy. At present, only one patient has died during follow-up due to liver metastases six years after the start of treatment. In carefully selected patients, this approach can be effective and safe, as long as a close follow-up is carried out after surgery. |
doi_str_mv | 10.3390/jcm11061616 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8956023</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2642491836</sourcerecordid><originalsourceid>FETCH-LOGICAL-c409t-c562a26c53ebe8c5d1962e797cc99748d325e244c2787342356cc4bd45a3f6d43</originalsourceid><addsrcrecordid>eNpdkU1rGzEQhkVJqYObU-9hIZdAcaqv1a4ugdTkCxwMaXPpRcizs7bM7sqRdhP876PUaXA6c5hh5uFlhpeQb4yeCaHpjzW0jFHFUn4ih5wWxYSKUhzs9SNyFOOapihLyVnxhYxELrjWkh-SP9PGdQ5sk82HHnyLMbN1jyH7NYTl3_k9RoTe-S6b-nbhOqyyZ9evsp_BwmrbrzDYzTarfcgenjDxd9jYzrc2fiWfa9tEPHqrY_Jwdfl7ejOZza9vpxezCUiq-wnkiluuIBe4wBLyimnFsdAFgNaFLCvBc-RSAi_KQkgucgUgF5XMrahVJcWYnO90N8OixQqw64NtzCa41oat8daZj5vOrczSP5lS54pykQRO3wSCfxww9qZ1EbBJf6AfouFKSsq41DqhJ_-haz-ELr33SiWElUIl6vuOguBjDFi_H8OoebXN7NmW6OP9-9_ZfyaJF2eEkws</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2642491836</pqid></control><display><type>article</type><title>Clinical Outcomes after Surgical Resection Combined with Brachytherapy for Uveal Melanomas</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Relimpio-López, Isabel ; Garrido-Hermosilla, Antonio Manuel ; Espejo, Francisco ; Gessa-Sorroche, María ; Coca, Lourdes ; Domínguez, Belen ; Díaz-Granda, María Jesús ; Ponte, Beatriz ; Cano, María José ; Rodríguez de la Rúa, Enrique ; Carrasco-Peña, Francisco ; Míguez, Carlos ; Saavedra, Jonathan ; Ontanilla, Antonio ; Caparrós-Escudero, Carlos ; Ríos, Juan José ; Terrón, José Antonio</creator><creatorcontrib>Relimpio-López, Isabel ; Garrido-Hermosilla, Antonio Manuel ; Espejo, Francisco ; Gessa-Sorroche, María ; Coca, Lourdes ; Domínguez, Belen ; Díaz-Granda, María Jesús ; Ponte, Beatriz ; Cano, María José ; Rodríguez de la Rúa, Enrique ; Carrasco-Peña, Francisco ; Míguez, Carlos ; Saavedra, Jonathan ; Ontanilla, Antonio ; Caparrós-Escudero, Carlos ; Ríos, Juan José ; Terrón, José Antonio</creatorcontrib><description>Currently, brachytherapy is the most commonly used therapeutic approach for uveal melanomas. Surgical resection by means of endoresection or exoresection is an alternative approach. The present report recounts our experience over 15 years in the treatment of uveal melanoma using a combined approach of resection surgery with brachytherapy. This is a single-center observational retrospective cohort study in which we describe clinical outcomes, complications and survival in 35 cases of melanoma of the iris or the ciliary body after a combination of surgery and brachytherapy or brachytherapy alone. Local treatment of the tumor was successful in all cases with surgery and brachytherapy. The most frequent complications were scleromalacia, bullous keratopathy, retinal toxicity, cataracts, hypotonia, and photophobia. There were three cases of recurrence, all of which were found in the group of patients who had received brachytherapy alone, and in one case we had to perform a secondary enucleation due to tumor growth after brachytherapy. At present, only one patient has died during follow-up due to liver metastases six years after the start of treatment. In carefully selected patients, this approach can be effective and safe, as long as a close follow-up is carried out after surgery.</description><identifier>ISSN: 2077-0383</identifier><identifier>EISSN: 2077-0383</identifier><identifier>DOI: 10.3390/jcm11061616</identifier><identifier>PMID: 35329942</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Clinical medicine ; Clinical outcomes ; Drug dosages ; Iris ; Melanoma ; Patients ; Radiation therapy ; Statistical analysis ; Surgery ; Tumors ; Ulcers</subject><ispartof>Journal of clinical medicine, 2022-03, Vol.11 (6), p.1616</ispartof><rights>2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 by the authors. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c409t-c562a26c53ebe8c5d1962e797cc99748d325e244c2787342356cc4bd45a3f6d43</citedby><cites>FETCH-LOGICAL-c409t-c562a26c53ebe8c5d1962e797cc99748d325e244c2787342356cc4bd45a3f6d43</cites><orcidid>0000-0003-0591-0401 ; 0000-0001-5417-1495 ; 0000-0001-5123-9597 ; 0000-0002-7664-676X ; 0000-0002-2872-2940</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8956023/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8956023/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35329942$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Relimpio-López, Isabel</creatorcontrib><creatorcontrib>Garrido-Hermosilla, Antonio Manuel</creatorcontrib><creatorcontrib>Espejo, Francisco</creatorcontrib><creatorcontrib>Gessa-Sorroche, María</creatorcontrib><creatorcontrib>Coca, Lourdes</creatorcontrib><creatorcontrib>Domínguez, Belen</creatorcontrib><creatorcontrib>Díaz-Granda, María Jesús</creatorcontrib><creatorcontrib>Ponte, Beatriz</creatorcontrib><creatorcontrib>Cano, María José</creatorcontrib><creatorcontrib>Rodríguez de la Rúa, Enrique</creatorcontrib><creatorcontrib>Carrasco-Peña, Francisco</creatorcontrib><creatorcontrib>Míguez, Carlos</creatorcontrib><creatorcontrib>Saavedra, Jonathan</creatorcontrib><creatorcontrib>Ontanilla, Antonio</creatorcontrib><creatorcontrib>Caparrós-Escudero, Carlos</creatorcontrib><creatorcontrib>Ríos, Juan José</creatorcontrib><creatorcontrib>Terrón, José Antonio</creatorcontrib><title>Clinical Outcomes after Surgical Resection Combined with Brachytherapy for Uveal Melanomas</title><title>Journal of clinical medicine</title><addtitle>J Clin Med</addtitle><description>Currently, brachytherapy is the most commonly used therapeutic approach for uveal melanomas. Surgical resection by means of endoresection or exoresection is an alternative approach. The present report recounts our experience over 15 years in the treatment of uveal melanoma using a combined approach of resection surgery with brachytherapy. This is a single-center observational retrospective cohort study in which we describe clinical outcomes, complications and survival in 35 cases of melanoma of the iris or the ciliary body after a combination of surgery and brachytherapy or brachytherapy alone. Local treatment of the tumor was successful in all cases with surgery and brachytherapy. The most frequent complications were scleromalacia, bullous keratopathy, retinal toxicity, cataracts, hypotonia, and photophobia. There were three cases of recurrence, all of which were found in the group of patients who had received brachytherapy alone, and in one case we had to perform a secondary enucleation due to tumor growth after brachytherapy. At present, only one patient has died during follow-up due to liver metastases six years after the start of treatment. In carefully selected patients, this approach can be effective and safe, as long as a close follow-up is carried out after surgery.</description><subject>Clinical medicine</subject><subject>Clinical outcomes</subject><subject>Drug dosages</subject><subject>Iris</subject><subject>Melanoma</subject><subject>Patients</subject><subject>Radiation therapy</subject><subject>Statistical analysis</subject><subject>Surgery</subject><subject>Tumors</subject><subject>Ulcers</subject><issn>2077-0383</issn><issn>2077-0383</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNpdkU1rGzEQhkVJqYObU-9hIZdAcaqv1a4ugdTkCxwMaXPpRcizs7bM7sqRdhP876PUaXA6c5hh5uFlhpeQb4yeCaHpjzW0jFHFUn4ih5wWxYSKUhzs9SNyFOOapihLyVnxhYxELrjWkh-SP9PGdQ5sk82HHnyLMbN1jyH7NYTl3_k9RoTe-S6b-nbhOqyyZ9evsp_BwmrbrzDYzTarfcgenjDxd9jYzrc2fiWfa9tEPHqrY_Jwdfl7ejOZza9vpxezCUiq-wnkiluuIBe4wBLyimnFsdAFgNaFLCvBc-RSAi_KQkgucgUgF5XMrahVJcWYnO90N8OixQqw64NtzCa41oat8daZj5vOrczSP5lS54pykQRO3wSCfxww9qZ1EbBJf6AfouFKSsq41DqhJ_-haz-ELr33SiWElUIl6vuOguBjDFi_H8OoebXN7NmW6OP9-9_ZfyaJF2eEkws</recordid><startdate>20220315</startdate><enddate>20220315</enddate><creator>Relimpio-López, Isabel</creator><creator>Garrido-Hermosilla, Antonio Manuel</creator><creator>Espejo, Francisco</creator><creator>Gessa-Sorroche, María</creator><creator>Coca, Lourdes</creator><creator>Domínguez, Belen</creator><creator>Díaz-Granda, María Jesús</creator><creator>Ponte, Beatriz</creator><creator>Cano, María José</creator><creator>Rodríguez de la Rúa, Enrique</creator><creator>Carrasco-Peña, Francisco</creator><creator>Míguez, Carlos</creator><creator>Saavedra, Jonathan</creator><creator>Ontanilla, Antonio</creator><creator>Caparrós-Escudero, Carlos</creator><creator>Ríos, Juan José</creator><creator>Terrón, José Antonio</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-0591-0401</orcidid><orcidid>https://orcid.org/0000-0001-5417-1495</orcidid><orcidid>https://orcid.org/0000-0001-5123-9597</orcidid><orcidid>https://orcid.org/0000-0002-7664-676X</orcidid><orcidid>https://orcid.org/0000-0002-2872-2940</orcidid></search><sort><creationdate>20220315</creationdate><title>Clinical Outcomes after Surgical Resection Combined with Brachytherapy for Uveal Melanomas</title><author>Relimpio-López, Isabel ; Garrido-Hermosilla, Antonio Manuel ; Espejo, Francisco ; Gessa-Sorroche, María ; Coca, Lourdes ; Domínguez, Belen ; Díaz-Granda, María Jesús ; Ponte, Beatriz ; Cano, María José ; Rodríguez de la Rúa, Enrique ; Carrasco-Peña, Francisco ; Míguez, Carlos ; Saavedra, Jonathan ; Ontanilla, Antonio ; Caparrós-Escudero, Carlos ; Ríos, Juan José ; Terrón, José Antonio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c409t-c562a26c53ebe8c5d1962e797cc99748d325e244c2787342356cc4bd45a3f6d43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Clinical medicine</topic><topic>Clinical outcomes</topic><topic>Drug dosages</topic><topic>Iris</topic><topic>Melanoma</topic><topic>Patients</topic><topic>Radiation therapy</topic><topic>Statistical analysis</topic><topic>Surgery</topic><topic>Tumors</topic><topic>Ulcers</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Relimpio-López, Isabel</creatorcontrib><creatorcontrib>Garrido-Hermosilla, Antonio Manuel</creatorcontrib><creatorcontrib>Espejo, Francisco</creatorcontrib><creatorcontrib>Gessa-Sorroche, María</creatorcontrib><creatorcontrib>Coca, Lourdes</creatorcontrib><creatorcontrib>Domínguez, Belen</creatorcontrib><creatorcontrib>Díaz-Granda, María Jesús</creatorcontrib><creatorcontrib>Ponte, Beatriz</creatorcontrib><creatorcontrib>Cano, María José</creatorcontrib><creatorcontrib>Rodríguez de la Rúa, Enrique</creatorcontrib><creatorcontrib>Carrasco-Peña, Francisco</creatorcontrib><creatorcontrib>Míguez, Carlos</creatorcontrib><creatorcontrib>Saavedra, Jonathan</creatorcontrib><creatorcontrib>Ontanilla, Antonio</creatorcontrib><creatorcontrib>Caparrós-Escudero, Carlos</creatorcontrib><creatorcontrib>Ríos, Juan José</creatorcontrib><creatorcontrib>Terrón, José Antonio</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of clinical medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Relimpio-López, Isabel</au><au>Garrido-Hermosilla, Antonio Manuel</au><au>Espejo, Francisco</au><au>Gessa-Sorroche, María</au><au>Coca, Lourdes</au><au>Domínguez, Belen</au><au>Díaz-Granda, María Jesús</au><au>Ponte, Beatriz</au><au>Cano, María José</au><au>Rodríguez de la Rúa, Enrique</au><au>Carrasco-Peña, Francisco</au><au>Míguez, Carlos</au><au>Saavedra, Jonathan</au><au>Ontanilla, Antonio</au><au>Caparrós-Escudero, Carlos</au><au>Ríos, Juan José</au><au>Terrón, José Antonio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical Outcomes after Surgical Resection Combined with Brachytherapy for Uveal Melanomas</atitle><jtitle>Journal of clinical medicine</jtitle><addtitle>J Clin Med</addtitle><date>2022-03-15</date><risdate>2022</risdate><volume>11</volume><issue>6</issue><spage>1616</spage><pages>1616-</pages><issn>2077-0383</issn><eissn>2077-0383</eissn><abstract>Currently, brachytherapy is the most commonly used therapeutic approach for uveal melanomas. Surgical resection by means of endoresection or exoresection is an alternative approach. The present report recounts our experience over 15 years in the treatment of uveal melanoma using a combined approach of resection surgery with brachytherapy. This is a single-center observational retrospective cohort study in which we describe clinical outcomes, complications and survival in 35 cases of melanoma of the iris or the ciliary body after a combination of surgery and brachytherapy or brachytherapy alone. Local treatment of the tumor was successful in all cases with surgery and brachytherapy. The most frequent complications were scleromalacia, bullous keratopathy, retinal toxicity, cataracts, hypotonia, and photophobia. There were three cases of recurrence, all of which were found in the group of patients who had received brachytherapy alone, and in one case we had to perform a secondary enucleation due to tumor growth after brachytherapy. At present, only one patient has died during follow-up due to liver metastases six years after the start of treatment. In carefully selected patients, this approach can be effective and safe, as long as a close follow-up is carried out after surgery.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>35329942</pmid><doi>10.3390/jcm11061616</doi><orcidid>https://orcid.org/0000-0003-0591-0401</orcidid><orcidid>https://orcid.org/0000-0001-5417-1495</orcidid><orcidid>https://orcid.org/0000-0001-5123-9597</orcidid><orcidid>https://orcid.org/0000-0002-7664-676X</orcidid><orcidid>https://orcid.org/0000-0002-2872-2940</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2077-0383 |
ispartof | Journal of clinical medicine, 2022-03, Vol.11 (6), p.1616 |
issn | 2077-0383 2077-0383 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8956023 |
source | MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central; PubMed Central Open Access |
subjects | Clinical medicine Clinical outcomes Drug dosages Iris Melanoma Patients Radiation therapy Statistical analysis Surgery Tumors Ulcers |
title | Clinical Outcomes after Surgical Resection Combined with Brachytherapy for Uveal Melanomas |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T18%3A23%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20Outcomes%20after%20Surgical%20Resection%20Combined%20with%20Brachytherapy%20for%20Uveal%20Melanomas&rft.jtitle=Journal%20of%20clinical%20medicine&rft.au=Relimpio-L%C3%B3pez,%20Isabel&rft.date=2022-03-15&rft.volume=11&rft.issue=6&rft.spage=1616&rft.pages=1616-&rft.issn=2077-0383&rft.eissn=2077-0383&rft_id=info:doi/10.3390/jcm11061616&rft_dat=%3Cproquest_pubme%3E2642491836%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2642491836&rft_id=info:pmid/35329942&rfr_iscdi=true |